유한양행의 렉라자 FDA 승인
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus...
https://www.prnewswire.com/news-rel...
유한양행이 성공했군요
FDA오피셜입니다
https://cm.asiae.co.kr/article/2024...
